Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATXINASDAQ:COCPNASDAQ:ORMPOTCMKTS:PVOTFNASDAQ:VBLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.34+31.8%$0.24$0.17▼$3.93$1.08M-0.09130,325 shs357 shsCOCPCocrystal Pharma$1.54+2.0%$1.54$1.12▼$3.26N/A2.0726,647 shs14,097 shsORMPOramed Pharmaceuticals$2.18+1.1%$2.21$1.82▼$3.09$88.24M1.59142,022 shs18,026 shsPVOTFBetterLife Pharma$0.00$0.03▼$0.38$21.70MN/A52,703 shs198,200 shsVBLTVascular Biogenics$0.40$0.10▼$6.74$423.91M0.772.19 million shs161,505 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics+31.80%+41.39%+30.73%+30.63%-89.97%COCPCocrystal Pharma+2.05%-0.65%-8.33%+8.45%-33.62%ORMPOramed Pharmaceuticals+1.11%+0.65%-3.36%+4.00%-14.02%PVOTFBetterLife Pharma0.00%0.00%0.00%0.00%0.00%VBLTVascular Biogenics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATXIAvenue Therapeutics2.596 of 5 stars0.04.00.04.62.00.01.9COCPCocrystal Pharma2.5086 of 5 stars3.55.00.00.00.61.70.0ORMPOramed Pharmaceuticals0.4524 of 5 stars0.03.00.00.01.00.80.6PVOTFBetterLife PharmaN/AN/AN/AN/AN/AN/AN/AN/AVBLTVascular BiogenicsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXIAvenue Therapeutics 0.00N/AN/AN/ACOCPCocrystal Pharma 3.00Buy$6.00289.61% UpsideORMPOramed Pharmaceuticals 2.00HoldN/AN/APVOTFBetterLife Pharma 0.00N/AN/AN/AVBLTVascular Biogenics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ORMP, COCP, PVOTF, ATXI, and VBLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/20/2025COCPCocrystal PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $6.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXIAvenue TherapeuticsN/AN/AN/AN/A$1.92 per shareN/ACOCPCocrystal PharmaN/AN/AN/AN/A$0.94 per shareN/AORMPOramed Pharmaceuticals$1.34M66.58N/AN/A$3.61 per share0.60PVOTFBetterLife PharmaN/AN/AN/AN/A$0.01 per shareN/AVBLTVascular Biogenics$660K0.00N/AN/A$0.32 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXIAvenue Therapeutics-$10.38M$18.350.02∞N/AN/A-471.57%-296.50%8/7/2025 (Estimated)COCPCocrystal Pharma-$17.50M-$1.57N/AN/AN/AN/A-135.12%-102.38%8/13/2025 (Estimated)ORMPOramed Pharmaceuticals-$19.06M-$0.44N/AN/AN/AN/A-11.34%-10.73%8/13/2025 (Estimated)PVOTFBetterLife Pharma-$14.78MN/AN/AN/AN/AN/A-205.15%-147.23%N/AVBLTVascular Biogenics-$32.30M-$0.21N/AN/AN/AN/A-73.45%-54.11%N/ALatest ORMP, COCP, PVOTF, ATXI, and VBLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025COCPCocrystal Pharma-$0.52-$0.23+$0.29-$0.23N/AN/A5/15/2025Q1 2025ORMPOramed Pharmaceuticals-$0.03-$0.19-$0.16-$0.19N/A$2.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATXIAvenue TherapeuticsN/AN/AN/AN/AN/ACOCPCocrystal PharmaN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/APVOTFBetterLife PharmaN/AN/AN/AN/AN/AVBLTVascular BiogenicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXIAvenue TherapeuticsN/A2.702.70COCPCocrystal PharmaN/A4.574.57ORMPOramed PharmaceuticalsN/A23.9423.94PVOTFBetterLife PharmaN/A3.623.62VBLTVascular BiogenicsN/A4.634.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXIAvenue Therapeutics17.34%COCPCocrystal Pharma6.72%ORMPOramed Pharmaceuticals12.73%PVOTFBetterLife PharmaN/AVBLTVascular Biogenics0.96%Insider OwnershipCompanyInsider OwnershipATXIAvenue Therapeutics1.80%COCPCocrystal Pharma28.14%ORMPOramed Pharmaceuticals13.70%PVOTFBetterLife Pharma34.77%VBLTVascular Biogenics6.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATXIAvenue Therapeutics43.18 million2.02 millionNot OptionableCOCPCocrystal Pharma10N/AN/ANot OptionableORMPOramed Pharmaceuticals1040.85 million35.25 millionOptionablePVOTFBetterLife PharmaN/A171.41 millionN/ANot OptionableVBLTVascular Biogenics777.64 million72.88 millionOptionableORMP, COCP, PVOTF, ATXI, and VBLT HeadlinesRecent News About These CompaniesVBL warns of financial impact of severance payments in second pillar reformSeptember 4, 2024 | ipe.comIMarket Unimpressed By VBL's 26% Jump In Net Profit, Shares Tank 5%July 30, 2024 | msn.comTom Sox move one step closer to VBL title with 7-5 win over PurcellvilleJuly 30, 2024 | cbs19news.comCTom Sox drop game one of the VBL South Division Series against Cavaliers, 4-1July 26, 2024 | cbs19news.comCBenign and Malignant Vascular Tumors of the Liver in AdultsMay 23, 2024 | medscape.comMVBL Shares Climb As Q1 Profits Soar 25%: Why Analysts Think There's More To ComeMay 14, 2024 | msn.comAlboGraft Polyester Vascular Graft from LeMaitreMay 7, 2024 | news-medical.netNTommy Garten elected to VBL Hall of FameMarch 28, 2024 | therecorderonline.comTControl of vascular morphogenesis and homeostasis through the angiopoietin–Tie systemFebruary 21, 2024 | nature.comNVascular News and ResearchNovember 25, 2023 | news-medical.netNVascular Biogenics (VBLT) Price Target Increased by 160.00% to 13.26November 2, 2023 | msn.comNotable Labs Closes Merger Transaction With VBL TherapeuticsOctober 16, 2023 | finance.yahoo.comVBL Therapeutics Announces Results of Annual and Special Shareholder MeetingOctober 12, 2023 | finance.yahoo.comVBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder MeetingOctober 4, 2023 | finance.yahoo.comVascular Biogenics Rises on Presentation HypeSeptember 9, 2023 | finance.yahoo.comVBLT Stock Sees Decline of Approximately -0.22% in Last Five DaysSeptember 7, 2023 | knoxdaily.comKVBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SECSeptember 6, 2023 | finance.yahoo.comVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTAugust 28, 2023 | businesswire.comVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTAugust 28, 2023 | businesswire.comVBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 14, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeORMP, COCP, PVOTF, ATXI, and VBLT Company DescriptionsAvenue Therapeutics NASDAQ:ATXI$0.34 +0.08 (+31.80%) As of 07/3/2025 11:23 AM EasternAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Cocrystal Pharma NASDAQ:COCP$1.54 +0.03 (+1.99%) As of 07/3/2025 01:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Oramed Pharmaceuticals NASDAQ:ORMP$2.18 +0.02 (+1.11%) Closing price 07/3/2025 01:10 PM EasternExtended Trading$2.18 0.00 (-0.14%) As of 07/3/2025 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.BetterLife Pharma OTCMKTS:PVOTFBetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.Vascular Biogenics NASDAQ:VBLTVascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.